What is the current valuation of the Pulmonary Drug Market as of 2024?

The Pulmonary Drug Market was valued at 42.93 USD Billion in 2024. Read More

What is the projected market valuation for the Pulmonary Drug Market in 2035?

The market is projected to reach 62.48 USD Billion by 2035. Read More

What is the expected CAGR for the Pulmonary Drug Market during the forecast period 2025 - 2035?

The expected CAGR for the Pulmonary Drug Market during 2025 - 2035 is 3.47%. Read More

Which segments are included in the Pulmonary Drug Market analysis?

The market analysis includes segments such as Type, Route of Administration, Indication, and Patient Type. Read More

What are the projected revenues for Bronchodilators in 2035?

Bronchodilators are projected to generate revenues between 22.0 USD Billion by 2035. Read More

How do corticosteroids perform in the Pulmonary Drug Market?

Corticosteroids are expected to reach a valuation of 15.0 USD Billion by 2035. Read More

What is the revenue forecast for inhalation drugs by 2035?

Inhalation drugs are anticipated to achieve revenues of 22.0 USD Billion by 2035. Read More

What is the expected market size for Chronic Obstructive Pulmonary Disease treatments in 2035?

Treatments for Chronic Obstructive Pulmonary Disease are projected to reach 22.0 USD Billion by 2035. Read More

Which companies are considered key players in the Pulmonary Drug Market?

Key players include Pfizer, Boehringer Ingelheim, GlaxoSmithKline, Novartis, AstraZeneca, Roche, Teva Pharmaceutical Industries, Mylan, and Sanofi. Read More

What is the anticipated revenue for pediatric pulmonary drugs by 2035?

Pediatric pulmonary drugs are expected to generate revenues between 10.0 USD Billion and 15.0 USD Billion by 2035. Read More

Pulmonary Drug Market

Pulmonary Drug Market Research Report By Drug Type (Bronchodilators, Corticosteroids, Combination Drugs, Antihistamines), By Route of Administration (Inhalation, Oral, Injection, Nasal), By Indication (Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Pulmonary Fibrosis), By Patient Type (Adult, Pediatric, Geriatric) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

3.47%

2024 Market Size

$ 42.93 Billion

2035 Market Size

$ 62.48 Billion

Pharmaceutical ● Updated April 2026 Report ID: MRFR/Pharma/41760-HCR | Pages: 200 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Type (USD Billion) | |
  1. 4.1.1 Bronchodilators | |
  2. 4.1.2 Corticosteroids | |
  3. 4.1.3 Combination Drugs | |
  4. 4.1.4 Antihistamines |
2. 4.2 Healthcare, BY Route of Administration (USD Billion) | |
  1. 4.2.1 Inhalation | |
  2. 4.2.2 Oral | |
  3. 4.2.3 Injection | |
  4. 4.2.4 Nasal |
3. 4.3 Healthcare, BY Indication (USD Billion) | |
  1. 4.3.1 Asthma | |
  2. 4.3.2 Chronic Obstructive Pulmonary Disease | |
  3. 4.3.3 Allergic Rhinitis | |
  4. 4.3.4 Pulmonary Fibrosis |
4. 4.4 Healthcare, BY Patient Type (USD Billion) | |
  1. 4.4.1 Adult | |
  2. 4.4.2 Pediatric | |
  3. 4.4.3 Geriatric |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Pfizer (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Boehringer Ingelheim (DE) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 GlaxoSmithKline (GB) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Novartis (CH) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 AstraZeneca (GB) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Roche (CH) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Teva Pharmaceutical Industries (IL) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Mylan (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Sanofi (FR) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TYPE |
7. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
8. 6.5 US MARKET ANALYSIS BY INDICATION |
9. 6.6 US MARKET ANALYSIS BY PATIENT TYPE |
10. 6.7 CANADA MARKET ANALYSIS BY TYPE |
11. 6.8 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
12. 6.9 CANADA MARKET ANALYSIS BY INDICATION |
13. 6.10 CANADA MARKET ANALYSIS BY PATIENT TYPE |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TYPE |
16. 6.13 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
17. 6.14 GERMANY MARKET ANALYSIS BY INDICATION |
18. 6.15 GERMANY MARKET ANALYSIS BY PATIENT TYPE |
19. 6.16 UK MARKET ANALYSIS BY TYPE |
20. 6.17 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
21. 6.18 UK MARKET ANALYSIS BY INDICATION |
22. 6.19 UK MARKET ANALYSIS BY PATIENT TYPE |
23. 6.20 FRANCE MARKET ANALYSIS BY TYPE |
24. 6.21 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
25. 6.22 FRANCE MARKET ANALYSIS BY INDICATION |
26. 6.23 FRANCE MARKET ANALYSIS BY PATIENT TYPE |
27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE |
28. 6.25 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
29. 6.26 RUSSIA MARKET ANALYSIS BY INDICATION |
30. 6.27 RUSSIA MARKET ANALYSIS BY PATIENT TYPE |
31. 6.28 ITALY MARKET ANALYSIS BY TYPE |
32. 6.29 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
33. 6.30 ITALY MARKET ANALYSIS BY INDICATION |
34. 6.31 ITALY MARKET ANALYSIS BY PATIENT TYPE |
35. 6.32 SPAIN MARKET ANALYSIS BY TYPE |
36. 6.33 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
37. 6.34 SPAIN MARKET ANALYSIS BY INDICATION |
38. 6.35 SPAIN MARKET ANALYSIS BY PATIENT TYPE |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY INDICATION |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY PATIENT TYPE |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TYPE |
45. 6.42 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
46. 6.43 CHINA MARKET ANALYSIS BY INDICATION |
47. 6.44 CHINA MARKET ANALYSIS BY PATIENT TYPE |
48. 6.45 INDIA MARKET ANALYSIS BY TYPE |
49. 6.46 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
50. 6.47 INDIA MARKET ANALYSIS BY INDICATION |
51. 6.48 INDIA MARKET ANALYSIS BY PATIENT TYPE |
52. 6.49 JAPAN MARKET ANALYSIS BY TYPE |
53. 6.50 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
54. 6.51 JAPAN MARKET ANALYSIS BY INDICATION |
55. 6.52 JAPAN MARKET ANALYSIS BY PATIENT TYPE |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY INDICATION |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY PATIENT TYPE |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE |
61. 6.58 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
62. 6.59 MALAYSIA MARKET ANALYSIS BY INDICATION |
63. 6.60 MALAYSIA MARKET ANALYSIS BY PATIENT TYPE |
64. 6.61 THAILAND MARKET ANALYSIS BY TYPE |
65. 6.62 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
66. 6.63 THAILAND MARKET ANALYSIS BY INDICATION |
67. 6.64 THAILAND MARKET ANALYSIS BY PATIENT TYPE |
68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE |
69. 6.66 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
70. 6.67 INDONESIA MARKET ANALYSIS BY INDICATION |
71. 6.68 INDONESIA MARKET ANALYSIS BY PATIENT TYPE |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE |
73. 6.70 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
74. 6.71 REST OF APAC MARKET ANALYSIS BY INDICATION |
75. 6.72 REST OF APAC MARKET ANALYSIS BY PATIENT TYPE |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE |
78. 6.75 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
79. 6.76 BRAZIL MARKET ANALYSIS BY INDICATION |
80. 6.77 BRAZIL MARKET ANALYSIS BY PATIENT TYPE |
81. 6.78 MEXICO MARKET ANALYSIS BY TYPE |
82. 6.79 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
83. 6.80 MEXICO MARKET ANALYSIS BY INDICATION |
84. 6.81 MEXICO MARKET ANALYSIS BY PATIENT TYPE |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE |
86. 6.83 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
87. 6.84 ARGENTINA MARKET ANALYSIS BY INDICATION |
88. 6.85 ARGENTINA MARKET ANALYSIS BY PATIENT TYPE |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT TYPE |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY INDICATION |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY PATIENT TYPE |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY INDICATION |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY PATIENT TYPE |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE |
103. 6.100 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
104. 6.101 REST OF MEA MARKET ANALYSIS BY INDICATION |
105. 6.102 REST OF MEA MARKET ANALYSIS BY PATIENT TYPE |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY INDICATION, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY PATIENT TYPE, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY PATIENT TYPE, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY INDICATION, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Pulmonary Drug Market Segmentation

Pulmonary Drug Market By Type (USD Billion, 2025-2035)

Bronchodilators
Corticosteroids
Combination Drugs
Antihistamines

Pulmonary Drug Market By Route of Administration (USD Billion, 2025-2035)

Inhalation
Oral
Injection
Nasal

Pulmonary Drug Market By Indication (USD Billion, 2025-2035)

Asthma
Chronic Obstructive Pulmonary Disease
Allergic Rhinitis
Pulmonary Fibrosis

Pulmonary Drug Market By Patient Type (USD Billion, 2025-2035)

Adult
Pediatric
Geriatric

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”